Angiogenesis and anti-angiogenic therapy in prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 2, 2013, Pages 122-131

  Mukherji, Deborah ^a   Temraz, Sally ^a   Wehbe, David ^a   Shamseddine, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Angiogenesis; Bevacizumab; Cabozantinib; Castration resistant prostate cancer; Sunitinib; Vascular endothelial growth factor

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CEDIRANIB; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; LENALIDOMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; PAZOPANIB; PLACEBO; PREDNISOLONE; PREDNISONE; SORAFENIB; SUNITINIB; TASQUINIMOD; TEMSIROLIMUS; THALIDOMIDE; TRC 105; TREBANANIB; UNCLASSIFIED DRUG; VANDETANIB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BACKACHE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; FATIGUE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; JAW OSTEONECROSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS; BEVACIZUMAB; CABOZANTINIB; CASTRATION RESISTANT PROSTATE CANCER; SUNITINIB; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84881252987     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.01.002     Document Type: Review

References (67)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60(September-October (5)):277-300.
2. La Vecchia C., Bosetti C., Lucchini F., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology 2010, 21(June (6)):1323-1360.
3. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 2010, 363(July (5)):411-422.
4. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376(October (9747)):1147-1154.
5. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 2011, 364(May (21)):1995-2005.
6. Parker C. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA). European multidisciplinary cancer congress 2011 2011.
7. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 2012, 367(September (13)):1187-1197.
8. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. American Journal of Pathology 1993, 143(August (2)):401-409.
9. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350(June (23)):2335-2342.
10. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006, 355(December (24)):2542-2550.
11. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 2007, 356(January (2)):115-124.
12. Gettman M.T., Pacelli A., Slezak J., et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999, 54(September (3)):479-485.
13. Strohmeyer D., Rossing C., Bauerfeind A., et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000, 45(November (3)):216-224.
14. Doll J.A., Reiher F.K., Crawford S.E., Pins M.R., Campbell S.C., Bouck N.P. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001, 49(December (4)):293-305.
15. Morrissey C., Dowell A., Koreckij T.D., et al. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010, 70(December (16)):1799-1808.
16. Huss W.J., Barrios R.J., Foster B.A., Greenberg N.M. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003, 54(January (1)):8-16.
17. Humphrey P.A., Zhu X., Zarnegar R., et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. American Journal of Pathology 1995, 147(August (2)):386-396.
18. Scher H.F.K., Saad F., Taplin M.E., et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. Journal of Clinical Oncology 2012, 30(Suppl. 5). [abstr LBA1].
19. Darshan M.S., Loftus M.S., Thadani-Mulero M., et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research 2011, 71(September (18)):6019-6029.
20. Roche P.J., Hoare S.A., Parker M.G. A consensus DNA-binding site for the androgen receptor. Molecular Endocrinology 1992, 6(December (12)):2229-2235.
21. Sieveking D.P., Lim P., Chow R.W., et al. A sex-specific role for androgens in angiogenesis. Journal of Experimental Medicine 2010, 207(February (2)):345-352.
22. Pallares J., Rojo F., Iriarte J., Morote J., Armadans L.I., de Torres I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histology and Histopathology 2006, 21(August (8)):857-865.
23. Huang C.N., Huang S.P., Pao J.B., et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Annals of Oncology 2012, 23(March (3)):707-713.
24. Kelly W.K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology 2012, 30(May (13)):1534-1540.
25. Michaelson M.D., Ou O.S., Sengeløv Y., et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2011, 29(Suppl.). [abstr 4515].
26. Celgene. Celgene Will Discontinue Phase III MAINSAIL(R) Trial in castrate-resistant prostate cancer, 2011 [cited 01.07.12]; Available from: http://ir.celgene.com/phoenix.zhtml%3Fc=111960%26p=irol-newsArticle%26ID=1633148%26highlight=
27. Hussain M.M.R.S., Sweeney C., Corn P.G., et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. Journal of Clinical Oncology 2011, 29(Suppl.). [abstr 4516].
28. Fleming M.T., Morris M.J., Heller G., Scher H.I. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nature Clinical Practice. Oncology 2006, 3(December (12)):658-667.
29. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research 2008, 14(October (19)):6302-6309.
30. Scher H.I., Jia X., de Bono J.S., et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology 2009, 10(March (3)):233-239.
31. Olmos D., Arkenau H.T., Ang J.E., et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Annals of Oncology 2009, 20(January (1)):27-33.
32. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology 1999, 17(November (11)):3461-3467.
33. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000, 92(February (3)):205-216.
34. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 2008, 26(March (7)):1148-1159.
35. Sonpavde G., Periman P.O., Bernold D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Annals of Oncology 2010, 21(February (2)):319-324.
36. Messiou C., Collins D.J., Giles S., de Bono J.S., Bianchini D., de Souza N.M. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. European Radiology 2011, 21(October (10)):2169-2177.
37. Picchio M., Spinapolice E.G., Fallanca F., et al. [(11)C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging 2012, 29(January (1)):13-26.
38. Smith M.R., Rathkopf S.C., Scher D.E., et al. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE). Journal of Clinical Oncology 2012, 30(Suppl.). [abstr 4513].
39. Yang L., You S., Kumar V., Zhang C., Cao Y. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. Journal of Experimental and Clinical Cancer Research 2012, 31(May (1)):40.
40. Reese D.M., Corry F.P., Novotny M., Holmgren W., Small E.E.J. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate Journal 2001, 3(2):65-70.
41. Picus J., Halabi S., Kelly W.K., et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011, 117(February (3)):526-533.
42. Di Lorenzo G., Figg W.D., Fossa S.D., et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. European Urology 2008, 54(November (5)):1089-1094.
43. Halabi S., George K.W., Morris D.J., Kaplan M.J., Small E.B.E.J. Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology 2011, 29(Suppl. 7). [abstr 189].
44. Antonarakis E.S., Carducci M.A. Targeting angiogenesis for the treatment of prostate cancer. Expert Opinion on Therapeutic Targets 2012, 16(April (4)):365-376.
45. Ross R.W., Galsky M.D., Febbo P., et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a prostate cancer clinical trials consortium trial. Cancer 2012, 118(October (19)):4777-4784.
46. Isambert N., Freyer G., Zanetta S., et al. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clinical Cancer Research 2012, 18(March (6)):1743-1750.
47. Van Cutsem E., Lakomy T.J., Prausova R., et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Annals of Oncology 2011, 22(Suppl. 5). [abstr O-0024].
48. Sanofi. Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (aflibercept), 2012 [07.11.12]; Available from: http://en.sanofi.com/Images/30138_20120405_ZALTRAP_BLA_VENICE_en.pdf.
49. Figg W.D., Hussain M.H., Gulley J.L., et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. Journal of Urology 2009, 181(March (3)):1104-1113. discussion 13.
50. Figg W.D., Dahut W., Duray P., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clinical Cancer Research 2001, 7(July (7)):1888-1893.
51. Ning Y.M., Gulley J.L., Arlen P.M., et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2010, 28(April (12)):2070-2076.
52. Keizman D., Zahurak M., Sinibaldi V., et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical Cancer Research 2010, 16(November (21)):5269-5276.
53. Adesunloye B., Ning H.X., Madan Y.M., et al. Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2012, 30(Suppl.). [abstr 4569].
54. Aragon-Ching J.B., Ning Y.M., Chen C.C., et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investigation 2009, 27(February (2)):221-226.
55. Dror Michaelson M., Regan M.M., Oh W.K., et al. Phase II study of sunitinib in men with advanced prostate cancer. Annals of Oncology 2009, 20(May (5)):913-920.
56. Ou Y.M.D.M., Sengeløv L., Saad F., et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2011, 29(Suppl.). [abstr 4515].
57. Makhov P.B., Golovine K., Kutikov A., et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Molecular Cancer Therapeutics 2012, 11(July (7)):1510-1517.
58. Chi K.N., Ellard S.L., Hotte S.J., et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology 2008, 19(April (4)):746-751.
59. Aragon-Ching J.B., Jain L., Gulley J.L., et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU International 2009, 103(June (12)):1636-1640.
60. Yakes F.M., Chen J., Tan J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular Cancer Therapeutics 2011, 10(December (12)):2298-2308.
61. EXELIXIS. Exelixis' Cabozantinib Meets Primary Endpoint in Phase 3 Clincial Trial for medullary thyroid cancer, 2011 [updated 24.10.11]; Available from: http://www.exelixis.com/investors-media/press-releases.
62. De Bono J.S., Rathkopf S.M., Corn D.E., et al. Cabozantinib (XL184) at 40mg in patients with metastatic castration resistant prostate cancer (mcrpc): results of a phase 2 non-randomized expansion cohort (NRE). Annals of Oncology 2012, 23(Suppl. 10). [abstr 8970].
63. Pili R., Haggman M., Stadler W.M., et al. Phase II randomized, double-blind. Placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology 2011, 29(October (30)):4022-4028.
64. Armstrong A.J., Stadler H.M., Gingrich W.M., et al. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of Clinical Oncology 2012, 30(Suppl.). [abstr 4550].
65. Karzai F.H., Adelberg A.A., Madan D., et al. A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2012, 30(Suppl.). [abstr 3043].
66. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6(November (5)):507-516.
67. Mita A.C., Takimoto C.H., Mita M., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clinical Cancer Research 2010, 16(June (11)):3044-3056.